Mainz, September 6, 2017 – Individualized cancer immunotherapy
Prof. Ugur Sahin, Managing Director (Science and Research) and Co-Founder of TRON, will talk at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in our hometown Mainz. His talk is titled “Individualized Cancer Immunotherapy – Exploring a new landscape” and will cover the implementation of an RNA-based approach to mobilize immunity against the full spectrum of cancer mutations. For one, we were able to demonstrate in mouse tumor models that a substantial fraction of the mutanome is immunogenic and that these neo-epitopes are preferably recognized by CD4+ T cells (Nature. 2015). In addition, a phase I study in humans with stage III and IV melanoma patients was conducted, where the patients were vaccinated with synthetic RNA encoding multiple neo-epitopes selected from their own cancer mutanome (Nature. 2017). The findings from preclinical and clinical studies will be presented together with the basic concepts behind individualized cancer immunotherapies and the exploited methods and technologies.